8-K: Monte Rosa Therapeutics Announces Positive Interim Data for MRT-2359 Phase 1/2 Study

Monte Rosa Therapeutics reports favorable safety and pharmacodynamic results from its Phase 1/2 study of MRT-2359, a GSPT1 degrader, in patients with MYC-driven solid tumors, selecting a recommended Phase 2 dose.

Summary

• Monte Rosa Therapeutics has provided an update on its Phase 1/2 clinical trial for MRT-2359, a drug targeting MYC-driven solid tumors.
• The study involved two dosing schedules: 5 days on/9 days off and 21 days on/7 days off.
• The 5/9 schedule identified 0.5 mg and 1 mg doses as having a favorable safety profile, while higher doses were not tolerated due to thrombocytopenia.
• The 21/7 schedule showed that 0.5 mg and 0.75 mg doses had a favorable safety profile.
• A 0.5 mg dose on the 21/7 schedule was selected as the recommended Phase 2 dose (RP2D).
• The study has enrolled patients with various tumor types, including lung, prostate, and breast cancers.
• Pharmacodynamic assessments showed approximately 60% degradation of the GSPT1 protein in tumor biopsies across all dose levels, which is consistent with preclinical studies.
• The company expects to share updated clinical data, including biomarker and activity data, in Q1 2025.

Sentiment

Score: 7

Explanation: The document presents positive interim safety and pharmacodynamic data, with a clear path forward for Phase 2 development. However, it lacks efficacy data and includes standard risk disclosures, resulting in a moderately positive sentiment.

Positives

• The 0.5 mg dose on the 21/7 schedule was well-tolerated and selected as the recommended Phase 2 dose.
• The drug achieved the target of approximately 60% GSPT1 degradation in tumor biopsies.
• The safety profile of MRT-2359 is favorable, with no signs of hypotension, cytokine release syndrome, or clinically significant hypocalcemia.
• The 21/7 dosing schedule is considered more patient-friendly than the 5/9 schedule.
• The company has initiated combination studies with other cancer therapies.

Negatives

• Doses of 1.5 mg or higher on the 5/9 schedule were above the maximum tolerated dose due to thrombocytopenia.
• The document does not provide any efficacy data, only safety and pharmacodynamic data.

Risks

• The clinical trial is still in its early stages, and further data is needed to confirm the efficacy of MRT-2359.
• The company's forward-looking statements are subject to numerous risks and uncertainties, as detailed in their annual report.
• The company has not independently verified third-party data and makes no representations as to its accuracy.

Future Outlook

Monte Rosa Therapeutics expects to share updated clinical data, including biomarker and activity data, from the MRT-2359 Phase 1/2 study in Q1 2025. They also plan to enroll potential Phase 2 expansion cohorts.

Management Comments

• Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics, stated that the latest interim results from the Phase 1/2 study of MRT-2359 continue to indicate a favorable safety profile and degradation of GSPT1 to desired levels.
• Markus Warmuth also mentioned that the company is pleased to confirm the selection of 0.5 mg daily at a 21 days on, 7 days off drug dosing schedule as the recommended Phase 2 dose.

Industry Context

This announcement is relevant to the biotechnology industry, particularly companies focused on developing novel cancer therapies. The use of molecular glue degraders is an emerging area of interest, and Monte Rosa's progress with MRT-2359 is being closely watched by investors and competitors.

Comparison to Industry Standards

• The document mentions that other GSPT1 degraders have reported safety limitations such as hypotension, cytokine release syndrome, and hypocalcemia, which were not observed with MRT-2359.
• The company's approach of using a 21 days on, 7 days off dosing schedule is aimed at improving patient compliance compared to the 5 days on, 9 days off schedule, which is a common challenge in cancer drug development.
• The 60% GSPT1 degradation target is based on preclinical studies, and achieving this level in human tumor biopsies is a positive sign, but further efficacy data is needed to compare to other cancer therapies.

Stakeholder Impact

• Shareholders may react positively to the favorable safety and pharmacodynamic data.
• Patients with MYC-driven solid tumors may benefit from the development of MRT-2359.
• Employees of Monte Rosa Therapeutics will continue to work on the development of this drug.

Next Steps

• Monte Rosa will continue to collect and evaluate clinical results from the MRT-2359 Phase 1/2 study.
• The company expects to share updated data, including biomarker and activity data, in Q1 2025.
• They will also be initiating Phase 2 expansion cohorts.

Key Dates

Keywords

MRT-2359, GSPT1 degrader, MYC-driven tumors, Phase 1/2 study, molecular glue degrader, oncology, clinical trial, biomarker, pharmacodynamics, safety